Literature DB >> 16515890

Widespread correction of lysosomal storage in the mucopolysaccharidosis type VII mouse brain with a herpes simplex virus type 1 vector expressing beta-glucuronidase.

Bradford K Berges1, Srikanth Yellayi, Brian A Karolewski, Richard R Miselis, John H Wolfe, Nigel W Fraser.   

Abstract

We have inoculated a herpes simplex virus type 1 (HSV-1) vector into a variety of sites in the mouse brain and assayed the regions of latency and expression of a beta-glucuronidase (GUSB) cDNA from the latency-associated transcript promoter. Injection sites used were somatosensory cortex, visual cortex, striatum, dorsal hippocampus, and CSF spaces. Latent vector was detected in regions at a distance from the respective injection sites, consistent with axonal transport of vector. Regions of GUSB activity varied by injection site and included cerebral cortex, striatum, thalamus, hypothalamus, substantia nigra, hippocampus, midbrain, pons, medulla, cerebellum, and spinal cord. After a single injection, GUSB enzymatic activity reached wild-type levels in several brain regions. GUSB was found in some areas without any detectable vector, indicative of axonal transport of GUSB enzyme. GUSB-deficient mice, which have the lysosomal storage disease mucopolysaccharidosis (MPS) VII, have lysosomal storage lesions in cells throughout the brain. Adult MPS VII mice treated by injection of vector into a single site on each side of the brain had correction of storage lesions in a large volume of brain. The potential for long-term, widespread correction of lysosomal storage diseases with HSV-1 vectors is discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16515890     DOI: 10.1016/j.ymthe.2005.12.017

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  8 in total

1.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

Review 2.  Gene therapy for mucopolysaccharidosis.

Authors:  Katherine P Ponder; Mark E Haskins
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

Review 3.  Progress in gene therapy for neurological disorders.

Authors:  Michele Simonato; Jean Bennett; Nicholas M Boulis; Maria G Castro; David J Fink; William F Goins; Steven J Gray; Pedro R Lowenstein; Luk H Vandenberghe; Thomas J Wilson; John H Wolfe; Joseph C Glorioso
Journal:  Nat Rev Neurol       Date:  2013-04-23       Impact factor: 42.937

Review 4.  Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.

Authors:  Dao Pan
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

5.  In Situ Hybridization for Detection of AAV-Mediated Gene Expression.

Authors:  Jacqueline E Hunter; Brittney L Gurda; Sea Young Yoon; Michael J Castle; John H Wolfe
Journal:  Methods Mol Biol       Date:  2019

6.  Neurologic, gastric, and opthalmologic pathologies in a murine model of mucolipidosis type IV.

Authors:  Bhuvarahamurthy Venugopal; Marsha F Browning; Cyntia Curcio-Morelli; Andrea Varro; Norman Michaud; Nanda Nanthakumar; Steven U Walkley; James Pickel; Susan A Slaugenhaupt
Journal:  Am J Hum Genet       Date:  2007-10-02       Impact factor: 11.025

7.  Bilateral single-site intracerebral injection of a nonpathogenic herpes simplex virus-1 vector decreases anxiogenic behavior in MPS VII mice.

Authors:  Wenpei Liu; Gerald Griffin; Trena Clarke; Michael K Parente; Rita J Valentino; John H Wolfe; Nigel W Fraser
Journal:  Mol Ther Methods Clin Dev       Date:  2015-01-28       Impact factor: 6.698

Review 8.  Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better?

Authors:  Shunji Tomatsu; Isabella Azario; Kazuki Sawamoto; Alice Silvia Pievani; Andrea Biondi; Marta Serafini
Journal:  J Inherit Metab Dis       Date:  2015-11-17       Impact factor: 4.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.